ArticleHemaSphere2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 56 citations in OpenAlex.
- Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.British journal of haematology · 2026Trial
- Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.JAMA oncology · 2026Trial
- Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.Blood cancer journal · 2025Trial
- Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.Blood advances · 2025Trial
- Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Trial
- Article
- Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial.British journal of haematology · 2026Article
- [Clinical characteristics of acute thrombocytopenia in newly diagnosed follicular lymphoma patients receiving obinutuzumab chemotherapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.Current oncology reports · 2026Review
- Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.HemaSphere · 2026Article
- Article
- Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.Blood advances · 2026Review
- Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system.Clinics (Sao Paulo, Brazil) · 2026Article
- Adverse event reporting patterns of rituximab and obinutuzumab in B-cell non-Hodgkin lymphoma: a FAERS pharmacovigilance study.Frontiers in immunology · 2026Article
- Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study.Frontiers in immunology · 2026Article
- Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy.American journal of translational research · 2026Article
- Obinutuzumab for the treatment of podocytopathy with concurrent suspected but unconfirmed B-cell lymphoproliferative disorder: a case report and literature review.Frontiers in immunology · 2026Review
- Obinutuzumab-induced acute thrombocytopenia and leukopenia in ANCA-associated glomerulonephritis: case report and literature review.Frontiers in immunology · 2026Review
- Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity.The AAPS journal · 2025Article
- Ocular Involvement in Post-Transplantation Lymphoproliferative Disorder: A Rare Case with Rituximab Hypersensitivity.The American journal of case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 16 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the trial met its primary end point, demonstrating improvement in investigator-assessed progression-free survival (PFS) with obinutuzumab-based versus rituximab-based immunochemotherapy in patients with FL. We report the results of the final analysis in the FL population, with an additional exploratory analysis in the MZL subgroup. Overall, 1202 patients with FL were randomized 1:1 to obinutuzumab- or rituximab-based immunochemotherapy followed by maintenance with the same antibody for up to 2 years. After a median 7.9 (range, 0.0-9.8) years of follow-up, PFS remained improved with obinutuzumab- versus rituximab-based immunochemotherapy, with 7-year PFS rates of 63.4% versus 55.7% (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.